As of 2026-09-15, the Relative Valuation of NGM Biopharmaceuticals Inc (NGM) is (15.44) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.54 USD, the upside of NGM Biopharmaceuticals Inc based on Relative Valuation is -1102.5%.
The range of the Relative Valuation is (13.10) - (20.34) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 6.7x - 12.2x | 7.7x |
| Forward P/E multiples | 7.7x - 11.9x | 10.4x |
| Fair Price | (13.10) - (20.34) | (15.44) |
| Upside | -950.8% - -1420.5% | -1102.5% |
| Date | P/E |